| __timestamp | Celldex Therapeutics, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 22746000000 |
| Thursday, January 1, 2015 | 4011000 | 21536000000 |
| Friday, January 1, 2016 | 102026000 | 21685000000 |
| Sunday, January 1, 2017 | 96171000 | 25354000000 |
| Monday, January 1, 2018 | 66449000 | 27091000000 |
| Tuesday, January 1, 2019 | 42672000 | 27556000000 |
| Wednesday, January 1, 2020 | 42534000 | 28427000000 |
| Friday, January 1, 2021 | 3068000 | 23402000000 |
| Saturday, January 1, 2022 | 1400000 | 24596000000 |
| Sunday, January 1, 2023 | 3008000 | 26553000000 |
| Monday, January 1, 2024 | 27471000000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for two industry players: Johnson & Johnson and Celldex Therapeutics, Inc., from 2014 to 2023.
Johnson & Johnson, a titan in the sector, consistently reported a cost of revenue averaging around $24.9 billion annually. Despite fluctuations, their cost efficiency remained robust, with a notable peak in 2020. In contrast, Celldex Therapeutics, a smaller entity, exhibited a more volatile pattern, with costs ranging from $1.4 million to $102 million. This disparity highlights the scale and operational differences between the two companies.
The data underscores the importance of strategic cost management, especially for smaller firms like Celldex, to remain competitive in a market dominated by giants like Johnson & Johnson.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Johnson & Johnson
Johnson & Johnson vs Merck & Co., Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Johnson & Johnson vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Johnson & Johnson and PTC Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Johnson & Johnson and Mesoblast Limited
Cost of Revenue Trends: Johnson & Johnson vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: AbbVie Inc. vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Pfizer Inc. and Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored